Local government's roles in community health and wellbeing in Australia: Insights from Tasmania.

Issue Addressed: Local governments are well-placed to respond to communities' health and wellbeing needs. However, in the Australian state of Tasmania, the sector's roles in that respect are unclear.

Methods: We interviewed 10 municipal personnel in Tasmania to understand their views on local governments' community health and wellbeing functions.

Tracing memories and meanings of festival landscapes during the COVID-19 pandemic.

COVID-19 has deeply affected mass gatherings and travel and, in the process, has transformed festivals, festival landscapes, and people's sense of place in relation to such events. In this article we argue that it is important to better understand how people's memories of festival landscapes are affected by these larger shifts. We worked from the premise that information-rich cases could provide some initial insights in this respect.

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.

FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified , but we previously only demonstrated transient cytostatic effects when treating -amplified DDLPS cells with NVP-BGJ398. Effects of the more potent FGFR inhibitor LY2874455 were investigated in three DDLPS cell lines by measuring effects on cell growth and apoptosis and also testing efficacy . Genome, transcriptome and protein analyses were performed to characterize the signaling components in the FGFR pathway.

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.

Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of and mutations is important for therapeutic decisions, but the invasiveness of traditional biopsies limits the possibilities for repeated sampling. Using targeted next-generation sequencing, we have analyzed circulating cell-free DNA from 50 GIST patients.

Preclinical Evaluation of Vemurafenib as Therapy for BRAF Mutated Sarcomas.

Unlabelled: The BRAF mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines.

Methods: Four sarcoma cell lines harboring the BRAFV600E mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (A673) and atypical synovial sarcoma (SW982), were treated with vemurafenib and the effects on cell growth, apoptosis, cell cycle progression and cell signaling were determined.

Results: Vemurafenib induced a strong cytostatic effect in SA-4 cells, mainly due to cell cycle arrest, whereas only moderate levels of apoptosis were observed.